Archived explainer. For the current picture see today's ACAD page.
ACADIA PHARMACEUTICA (ACAD) is up +10.79% in the latest session. Our newswire has captured 4 stories on ACAD across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Acadia Pharmaceuticals (ACAD) shares rose 10.79% to $18.28 as the company confirmed that the Federal Circuit Court of Appeals heard oral arguments in a patent dispute concerning its lead drug, Nuplazid. The positive market reaction followed the court session, with the company expecting a decision in the first half of 2027.
Acadia Pharmaceuticals announced that the Federal Circuit heard oral arguments in the NUPLAZID 34 Mg Capsule Patent Appeal. The company stated it expects a decision on the appeal in the first half of 2027. This legal development regarding the formulation patent for its primary revenue driver was the primary catalyst for the session's gains.
Additionally, the company announced it will present data for remlifanserin at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference. Deutsche Bank adjusted its price target for the stock to $30. The company also joined a public service announcement campaign titled "The Rare Truth."
The stock printed 20 fresh 52-week highs on November 10, 2026. The 52-week range for the stock is $15.86 to $30.96. Fundamentals show a market cap of $3.7B, a P/E ratio of 7.9, and revenue growth of 14.8% over the trailing twelve months. The net margin stands at 30.1%, and the beta is 0.89.
Over the last eight sessions, the stock moved down 11.2% from $20.59 to $18.28 before the current rally. Recent insider activity includes a sale by Mark C. Schneyer, EVP and CFO, on October 30, 2026. In the last 90 days, there were zero insider buys and one sell totaling $69K. Congressional disclosures show one sale of $15,001 to $50,000 by Donald J. Trump on July 29, 2026.
Investors will monitor the outcome of the Federal Circuit appeal, with a decision expected in the first half of 2027. The company will also present remlifanserin data at the 2026 CTAD Conference.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Acadia Pharmaceuticals (ACAD) stock gains as an appeal court hears oral arguments regarding a patent dispute related to its lead drug, Nuplazid. Read more here.
More on ACAD: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ACAD move explainers: 2026-11-11 · 2026-11-10 · 2026-11-09 · 2026-09-25 · 2026-09-24 · 2026-08-26